JAK2 and ovarian carcinoma: Studies using ovarian cancer cell lines like SKOV3 and PA-1 reported that free melittin treatment upregulates death receptors (DR3, DR4, DR6), activates caspase-3 and caspase-8, and inhibits the pro-survival Janus kinase 2 (JAK2)/STAT3 pathway [77].